European Commission approves Oncopeptides' Pepaxti for the treatment of patients with relapsed refractory multiple myelo

(Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for...

Related Keywords

France ,Germany ,Norway ,Iceland ,Stockholm ,Sweden ,United Kingdom ,Italy ,Liechtenstein ,Spain ,Lichtenstein ,Oncopeptides Pepaxti ,Rolf Gulliksen ,Jakob Lindberg ,European Commission ,Global Head Of Corporate Communications ,Nasdaq Stockholm ,European Economic Area ,Global Head ,Corporate Communications ,Mid Cap ,